Premium
Flutamide has no effect on adrenal androgen response to acute ACTH stimulation in patients with prostatic cancer
Author(s) -
Carlström Kjell,
Pousette Åke,
Stege Reinhard
Publication year - 1990
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990170305
Subject(s) - flutamide , medicine , androgen , stimulation , endocrinology , cancer , prostate cancer , antiandrogen , hormone , androgen receptor
Abstract Basal levels and adrenocorticotropic hormone (ACTH)‐induced increments (Δ‐values) of serum cortisol, dehydroepiandrosterone (DHA), dehydroepiandrosterone sulfate (DHAS), 4‐androstene‐3,17‐dione (A4), and 17‐hydroxyprogesterone (170HP); basal testosterone (T), luteinizing hormone (LH), serum ASAT, gamma‐GT, and albumin were measured in prostatic cancer patients before and after 6 months of treatment with LH‐RH‐agonist, with flutamide, and with LH‐RH‐agonist + flutamide, respectively. Basal DHA and DHAS were decreased during flutamide and LH‐RH‐agonist + flutamide treatment and basal A4 during treatment with LH‐RH‐agonist and with LH‐RH‐agonist + flutamide. Basal 170HP, T, and LH decreased during LH‐RH‐agonist and LH‐RH‐agonist + flutamide treatment and increased during single drug flutamide treatment. Slightly decreased Δ cortisol values were observed during LH‐RH‐agonist and during flutamide treatment and slightly increased Δ 170HP values during LH‐RH‐agonist and LH‐RH‐agonist + flutamide treatment. Values for Δ DHA and Δ A4 were completely unaffected by any of the treatment regimens. Elevated ASAT values were observed during treatment with flutamide and with LH‐RH‐agonist + flutamide. It is concluded that flutamide has no effect on the adrenal androgen response to acute ACTH stimulation.